Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06747832 | INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer(iNK-SCLC) | enrolling by invitation | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 |
| Dec 20, 2024 |
| clinicaltrials |
| NCT06532591 | Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC | recruiting | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06745830 | Lymph Node Pathologic Grading Strategy | recruiting | — | 2,998 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06742021 | Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer | recruiting | N/A | 195 | Yunnan Cancer HospitalOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT05879068 | A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC | active not recruiting | Phase 2 | 99 | Biotheus Inc.INDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06705465 | Cross-sectorial Rehabilitation of Patients with Lung Cancer | recruiting | N/A | 130 | Camilla BalleOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06738680 | PRedictive Value of Multiparametric Dynamic WB 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immunotherapy Efficacy in Advanced Non-small-cell Lung Cancer: PROFIL-1(PROFIL-1) | not yet recruiting | — | 120 | University Hospital, BrestOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06739421 | The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial | not yet recruiting | N/A | 1,040 | China-Japan Friendship HospitalOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06737107 | Multicenter Analysis of Different Approaches in Segmentectomies in Early-stage Lung Cancer(ANASEGME) | recruiting | — | 472 | Scientific Institute San RaffaeleOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04170634 | Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study(MEKANOS) | recruiting | — | 220 | Hospices Civils de LyonOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06252233 | Improvement of Quality of Life (QoL) Using Preference-Oriented QoLMonitoring in Patients with Lung Cancer(LePaLuMo) | recruiting | N/A | 220 | University of BayreuthOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06467617 | Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC | recruiting | Phase 2 | 35 | Beijing Chest Hospital, Capital Medical UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06704620 | Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 430 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06734182 | Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer(neovision) | recruiting | Phase 2 | 25 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735508 | MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer | not yet recruiting | Early Phase 1 | 40 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06736561 | A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients. | not yet recruiting | — | 100 | Harbin Medical UniversityOTHER | 0 | Dec 16, 2024 | clinicaltrials |
| NCT06725225 | Machine Learning for Predicting and Managing Quality of Life in Lung Cancer Immunotherapy Patients | not yet recruiting | N/A | 200 | Second Affiliated Hospital of Zunyi Medical UniversityOTHER | 0 | Dec 13, 2024 | clinicaltrials |
| NCT02515760 | Tumor-specific T Cells in Lung Cancer | active not recruiting | N/A | 120 | University Hospital HeidelbergOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT04794010 | A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer(FINN) | active not recruiting | — | 825 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | recruiting | Phase 3 | 180 | Luye Pharma Group Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06575439 | An Observational Study of Predictors and Outcomes of Lung Cancer in Never-smokers in the UK(OLIVE) | recruiting | — | 225 | University College London HospitalsOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06647836 | The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma | enrolling by invitation | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06730477 | Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma | enrolling by invitation | — | 500 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06730503 | Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer | recruiting | — | 250 | Shanghai Chest HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health(COACH) | recruiting | N/A | 625 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06728852 | Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study(Vigor) | recruiting | Phase 2 | 32 | Li-kun ChenOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06019455 | The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy. | recruiting | — | 500 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06423690 | First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System | recruiting | N/A | 15 | Snipe MedicalINDUSTRY | 3 | Dec 10, 2024 | clinicaltrials |
| NCT06727370 | Cognitive Screening in Lung Cancer Patients | recruiting | — | 200 | European Institute of OncologyOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06247280 | Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation | active not recruiting | — | 2,001 | Yuhan CorporationINDUSTRY | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03934866 | The SUMMIT Study: A Cancer Screening Study(SUMMIT) | active not recruiting | — | 13,035 | University College, LondonOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06718309 | Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC | recruiting | Phase 2 | 40 | First People's Hospital of HangzhouOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06719336 | Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | not yet recruiting | Phase 3 | 182 | Anhui Shi, MDOTHER | 0 | Dec 5, 2024 | clinicaltrials |
| NCT05212103 | PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9(CANSI) | enrolling by invitation | — | 30 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04956692 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | active not recruiting | Phase 3 | 531 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Dec 3, 2024 | clinicaltrials |
| NCT06644430 | Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma | recruiting | — | 470 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05598528 | Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)(PRECISE) | recruiting | — | 210 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711939 | Vocorder Device Validation in Clinical Settings - Continuous Monitoring of Individuals (Vocorder Clinical Validation-VCV)(VCV) | not yet recruiting | — | 515 | Mitera HospitalOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT00471978 | DNA Analysis of Blood and Tissue from Patients with Lung Cancer | recruiting | — | — | Massachusetts General HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT03029325 | Molecular and Genetic Analysis of Lung Cancer | recruiting | — | 15,000 | Massachusetts General HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05945745 | Molecular Analysis and Treatment Options of SCLC | recruiting | — | 500 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06451029 | Prevention of Smoking Related Diseases(LSP-3) | recruiting | — | 189 | Scientific Institute San RaffaeleOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06470607 | The Lymphocytic Infiltrate of Lung Tumors.(TREGILC) | recruiting | — | 70 | Scientific Institute San RaffaeleOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06626243 | Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers(IMMUNORATS) | recruiting | — | 140 | Scientific Institute San RaffaeleOTHER | 2 | Nov 29, 2024 | clinicaltrials |
| NCT06709274 | Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC(MOTION-NSCLC) | not yet recruiting | N/A | 342 | Guangdong Association of Clinical TrialsOTHER | 1 | Nov 29, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 24, 2024source: clinicaltrials